Furthermore, BaP-treated PBMCs from psoriasis patient-derived exosomes upregulated the expression of proinflammatory cytokines, including IL-6, IL-17A, IL-22, IL-23, and IFN-γ, in recipient PBMCs from healthy controls, in contrast to HC PBMCs treated with PBMCs from non-treated psoriasis patient-derived exosomes. The gene discussed is IL17A; the disease is psoriasis.